Jonathan Friedberg, Director of Wilmot Cancer Institute, Rochester NY, Editor-in-Chief at Journal of Clinical Oncology, shared a post on X:
“This elegant study should inform lymphoma classification and trials focusing on TP53-mutant and high-VAF DLBCL. Future studies should explore whether these concepts are valid in other histologies with TP53 mutations such as MCL and CLL.”
Title: Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma
Authors: Manik Uppal, Bhavneet Bhinder, Andrew R. Marderstein, Connie Lee Batlevi, Lorenzo Falchi, Paul Hamlin, Steven Horwitz, Anita Kumar, Ariela Noy, Andrew D. Zelenetz, Jennifer K. Lue, Pallawi Torka, Zachary D. Epstein-Peterson, Maria Arcila, Ahmet Dogan, Brandon Imber, Joachim Yahalom, Santosha A. Vardhana, Andrew Intlekofer, Sandeep Raj, Roni Shouval, Brendan Hodkinson, Matthew E. Stokes, Adam S. Kittai, Joshua D. Brody, Olivier Elemento, Gilles Salles, Erel Joffe
Other articles featuring Jonathan Friedberg on OncoDaily.